Patents Assigned to ALECTOR LLC
  • Uses of Siglec-9 ECD Fusion Molecules in Cancer Treatment
    Publication number: 20260126446
    Abstract: The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and/or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and/or Siglec-9, and in some embodiments also CD68 and/or sialic acid expression in tumor or immune cells.
    Type: Application
    Filed: November 6, 2023
    Publication date: May 7, 2026
    Applicant: Alector LLC
    Inventors: Samuel Nalle, Spencer Liang
  • PILRA Antibodies and Methods of Use Thereof
    Publication number: 20260070976
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PIL-RA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or anti-gen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.
    Type: Application
    Filed: February 29, 2024
    Publication date: March 12, 2026
    Applicant: Alector LLC
    Inventors: Samuel Nalle, Ling Leung, Yong Wang, Angie Grace Yee
  • Anti-IL18 Binding Protein Antibodies and Methods of Use Thereof
    Publication number: 20250333523
    Abstract: The present disclosure is generally directed to compositions that include monovalent antibodies, e.g., monoclonal monovalent antibodies that specifically bind a IL18BP polypeptide, e.g., a mammalian IL18BP polypeptide or human IL18BP polypeptide, and use of such compositions in treating an individual in need thereof.
    Type: Application
    Filed: July 3, 2025
    Publication date: October 30, 2025
    Applicant: Alector LLC
    Inventors: Farah Riad Itani, Angie Grace Yee, Yong Wang, Wei Li, Wei-Hsien Ho, Marina Roell, Seung-Joo Lee, Spencer Liang, Li Zhou, Belvin Gong
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250297016
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2025
    Publication date: September 25, 2025
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250270319
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 6, 2025
    Publication date: August 28, 2025
    Applicant: Alector LLC
    Inventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
  • Anti-Sortilin antibodies and methods of use thereof
    Patent number: 12358991
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 15, 2025
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
    Publication number: 20250223365
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: July 18, 2024
    Publication date: July 10, 2025
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
  • Anti-MS4A4A antibodies and methods of use thereof
    Patent number: 12331111
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: June 17, 2025
    Assignee: Alector LLC
    Inventors: Philip Kong, Herve Rhinn, Tina Schwabe, Angie Yee, Ilaria Tassi, Muhammad Abbas Alhawagri, Arnon Rosenthal
  • Anti-MS4A4A antibodies and methods of use thereof
    Patent number: 12331112
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: June 17, 2025
    Assignee: Alector LLC
    Inventors: Philip Kong, Herve Rhinn, Tina Schwabe, Angie Yee, Ilaria Tassi, Muhammad Abbas Alhawagri, Arnon Rosenthal
  • Anti-SIRPa Antibodies and Methods of Use Thereof
    Publication number: 20250179189
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 19, 2025
    Publication date: June 5, 2025
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
  • Anti-TMEM106B antibodies and methods of use thereof
    Patent number: 12319734
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: June 3, 2025
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Eric Brown, Tina Schwabe, Angie Yee, Herve Rhinn
  • Anti-sortilin antibodies and methods of use thereof
    Patent number: 12297277
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: May 13, 2025
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
  • Anti-SIRP-Alpha Antibodies and Methods of Use Thereof
    Publication number: 20250144209
    Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
    Type: Application
    Filed: January 9, 2025
    Publication date: May 8, 2025
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
  • ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250145709
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: January 9, 2025
    Publication date: May 8, 2025
    Applicant: Alector LLC
    Inventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
  • Anti-Siglec-5 antibodies and methods of use thereof
    Patent number: 12258398
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 25, 2025
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Rashmi Bankoti, Helen Lam, Arnon Rosenthal
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20250092144
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: November 22, 2024
    Publication date: March 20, 2025
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • Anti-TREM1 Antibodies and Methods of Use Thereof
    Publication number: 20250092131
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: September 4, 2024
    Publication date: March 20, 2025
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
  • METHODS OF USE OF ANTI-TREM2 ANTIBODIES
    Publication number: 20250084165
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: August 15, 2024
    Publication date: March 13, 2025
    Applicant: Alector LLC
    Inventors: Michael F. WARD, Sam JACKSON
  • Anti-CD33 antibodies and methods of use thereof
    Patent number: 12247073
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 11, 2025
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Wei-Hsien Ho, Leonard G. Presta, Arnon Rosenthal
  • Anti-Siglec-7 antibodies and methods of use thereof
    Patent number: 12227568
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: February 18, 2025
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Seung-Joo Lee, Helen Lam, Wei-Hsien Ho, Arnon Rosenthal